Home › Research › Treatments
Safety profiles of lecanemab: A systematic review and meta-analysis of randomized controlled trials and real-world evidence
Qi L, Zheng F, Tu M, Abdullah R, Zhao Y, Su X, Zhou D, Peng G.. The journal of prevention of Alzheimer's disease, 2026-01-01
Topic: Risk, prevention and care in population studies
Plain-language summary
Background Safety profiles of lecanemab, an anti-amyloid-β antibody for the treatment of early Alzheimer's disease (AD), remain uncertain and may vary between randomized controlled trials (RCTs) and real-world evidence (RWE) studies. Objectives This systematic review and meta-analysis aimed to evaluate the safety, tolerability, and acceptability of lecanemab based on findings from both RCTs and emerging RWE studies. Methods We systematically searched major databases and clinical trial registries from their inception to June 2025. Random-effects meta-analyses were performed to estimate the pooled incidence of key safety outcomes, including amyloid-related imaging abnormalities (ARIA), infusion-related reactions (IRRs), and treatment discontinuation (due to ARIA, adverse events [AEs], or any cause). The risk of ARIA according to the ApoE4 genotype was assessed via relative risk (RR). This study was registered with PROSPERO (No. CRD420251110679). Results A total of two RCTs and five RWE studies encompassing 1576 patients were included. The pooled ARIA incidence was 19% (95% CI: 16%-23%), which was significantly modulated by ApoE4 status (RR 1.45 for heterozygotes, 3.54 for homozygotes vs noncarriers) and the pooled symptomatic ARIA incidence was 3% (95% CI: 2%-4%). IRRs occurred in 26% (95% CI: 19%-34%), with heterogeneity reduced in patients receiving specific pre-infusion prophylaxis. The pooled rate of discontinuation due to AEs was 8% (95% CI: 5%-11%), with discontinuation due to ARIA occurring in 5% (95% CI: 3%-7%) of patients in RWE studies. Conclusions Lecanemab-related ARIA demonstrates a clear ApoE4 gene-dose effect, supporting routine ApoE4 genotyping before treatment. Standardizing pre-infusion prophylaxis may reduce variability in IRRs incidence, while prompt recognition and management of ARIA are critical for improving treatment tolerability. These findings provide important evidence to support the safe clinical use of lecanemab.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Qi, L., Zheng, F., Tu, M., Abdullah, R., Zhao, Y., Su, X., et al. (2026). Safety profiles of lecanemab: A systematic review and meta-analysis of randomized controlled trials and real-world evidence. The journal of prevention of Alzheimer's disease. https://doi.org/10.1016/j.tjpad.2025.100473
Vancouver
Qi L, Zheng F, Tu M, Abdullah R, Zhao Y, Su X, et al. Safety profiles of lecanemab: A systematic review and meta-analysis of randomized controlled trials and real-world evidence. The journal of prevention of Alzheimer's disease. 2026. doi:10.1016/j.tjpad.2025.100473. PMID: 41478817.
BibTeX
@article{qi2026-41478817,
author = {Qi, L. and Zheng, F. and Tu, M. and Abdullah, R. and Zhao, Y. and Su, X. and Zhou, D. and Peng, G.},
title = {{Safety profiles of lecanemab: A systematic review and meta-analysis of randomized controlled trials and real-world evidence}},
journal = {The journal of prevention of Alzheimer's disease},
year = {2026},
doi = {10.1016/j.tjpad.2025.100473},
pmid = {41478817},
url = {https://doi.org/10.1016/j.tjpad.2025.100473}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Results A total of two RCTs and five RWE studies encompassing 1576 patients were included.
- The pooled ARIA incidence was 19% (95% CI: 16%-23%), which was significantly modulated by ApoE4 status (RR 1.45 for heterozygotes, 3.54 for homozygotes vs noncarriers) and the pooled symptomatic ARIA incidence was 3% (95% CI: 2%-4%).
- These findings provide important evidence to support the safe clinical use of lecanemab.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designsystematic review
- Participants1,576
- Effect sizeRR 1.45
- Evidence strengthHigh
How this study scored 90/100
Published in a peer-reviewed journal, and it is a systematic review of all the studies on the question. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 52 of the 58 points we could judge it on, which is 90 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (The journal of prevention of Alzheimer's disease) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 12 / 12 | A systematic review of all the studies on the question |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 3 / 4 | 1,576 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | A review of other studies — randomization is not credited here |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41478817) |
| Free to read | 2 / 2 | Free to read |
| Points | 52 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 52 of the 58 points we could judge it on is 90 out of 100. |
| Total | 90 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also tagged “profile”
5 studies in the library carry the topic tag “profile”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 5 tagged studies.